NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products
Using living cells for functional assays such as ADCC, ADCVI and Cytokine Release Assays approximates closely what one would see in live animal models. Through the use of NK-92® natural killer cells in these assays, assay variability and unreliability are minimized. For this reason, NK-92® cells are rapidly becoming the preferred next-generation bioanalytical testing solution among large pharma commercial developers, biosimilar developers, medical research institutions, universities and the global research community.
Through a limited arrangement, Brink Biologics is pleased to announce
that the company has non-exclusively licensed its next generation
bioanalytical testing solution to
“This agreement demonstrates the respect that research institutions have
for NantKwest’s proprietary rights in its innovative cell lines and
foundational technologies. Every laboratory should get its NK-92® cells
from Brink Biologics, which is the only licensed commercial and research
distributor of genuine NK-92®,” said
Dr. Soon-Shiong continued, “These novel and proprietary cells form the
foundation for NantKwest’s clinical-stage aNK™, haNK®, and t-haNK™
natural killer cell-based therapeutics programs and, through Brink
Biologics’ offering, they also represent a unique, next generation
bioanalytical testing solution. We are therefore very pleased to
announce this license agreement with
About Brink Biologics
NEUKOPANEL is a trademark of
For additional information and licensing inquiries, please visit www.brinkbiologics.com.
With the capacity to grow active killer cells as a living cancer therapy, our NK cells have been designed to induce cell death against cancers and virally infected cells by several mechanisms, including: (i) innate killing, whereby all of our NK platforms recognize the stress proteins typically found on cancer cells, which, upon binding, release toxic granules to immediately kill their targets; (ii) antibody-mediated killing with our haNK® platform, which are NK cells engineered to express antibody receptors that can bind to therapeutic antibody products, thereby enhancing the cancer cell killing effect of that antibody; and (iii) Chimeric Antigen Receptor directed killing using the taNK® platform, which includes NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells. All three modes of killing (innate, antibody-mediated, and CAR directed killing) are employed by our t-haNK™ platform, which is an innovative combination of our aNK, haNK® and taNK® platforms in a single product.
Our haNK®, and t-haNK™ platforms have been designed to address certain limitations of CAR T-cell therapy including the capability to infuse cell therapy in an outpatient setting which allows for potential reduction of risk for serious cytokine storms and protracted serious adverse events. In Phase I and II clinical trials in patients with late stage cancer, our NK cells have been administered as an investigational outpatient infusion safely with greater than 300 infusions to date at a dose of 2 billion cells per infusion.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs, we believe
NK-92, aNK, haNK, taNK, and t-haNK are trademarks of
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning or implying the
Company will be successful in improving the treatment of cancer. Risks
and uncertainties related to this endeavor include, but are not limited
Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
These and other risks regarding our business are described in detail in